Ophthalmic compositions comprising F6H8
Administering semifluorinated alkanes like F(CF2)4(CH2)5H to enrich ophthalmic tissues addresses the limitations of current treatments by providing sustained lubrication and reducing dry eye symptoms effectively, while avoiding visual disturbances and contamination risks.
Patent Information
- Application Number
- US18/439258
- Authority / Receiving Office
- US · United States
- Patent Type
- Patents(United States)
- Current Assignee / Owner
- Priority Date
- 2017-10-04
- Filing Date
- 2024-02-12
- Publication Date
- 2026-03-10
- Estimated Expiration
- 2038-10-03
AI Technical Summary
Current treatments for keratoconjunctivitis sicca and Meibomian gland dysfunction, such as artificial tears and ophthalmic emulsions, often cause visual disturbances and are difficult to manufacture in sterile form, and preservatives can be damaging to the eye, while existing semifluorinated alkane compositions do not provide effective enrichment or delayed release in ophthalmic tissues.
A method of administering a semifluorinated alkane, such as F(CF2)4(CH2)5H, F(CF2)4(CH2)6H, F(CF2)6(CH2)6H, or F(CF2)6(CH2)8H, to enrich ophthalmic tissues and provide delayed release, optionally without active drugs, in the form of liquid drops, typically twice daily, to treat dry eye disease and Meibomian gland dysfunction.
The method effectively enriches ophthalmic tissues with semifluorinated alkanes, providing sustained lubrication and tear film supplementation, reducing ocular surface damage and symptoms of dryness without visual disturbances, and is cost-effective and less prone to contamination.